Your session is about to expire
← Back to Search
Probiotic Therapy
SYNB1618 for Phenylketonuria (SynPheny-1 Trial)
Phase 2
Waitlist Available
Research Sponsored by Synlogic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 43
Awards & highlights
SynPheny-1 Trial Summary
This study is evaluating whether a drug may help treat a genetic disorder.
Eligible Conditions
- Phenylketonuria
SynPheny-1 Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 43
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 43
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Changes from baseline in labeled Phe (D5-Phe) in plasma
Secondary outcome measures
Changes from baseline in fasting levels of plasma Phe
Incidence of Treatment-Emergent Adverse Events
SynPheny-1 Trial Design
2Treatment groups
Experimental Treatment
Group I: SYNB1934Experimental Treatment1 Intervention
Dose ramp of SYNB1934
Group II: SYNB1618Experimental Treatment1 Intervention
Dose ramp of SYNB1618
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SYNB1934
2021
Completed Phase 2
~130
SYNB1618
2021
Completed Phase 2
~200
Find a Location
Who is running the clinical trial?
SynlogicLead Sponsor
9 Previous Clinical Trials
480 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger